Whole genome sequencing
- Algorithms
- Billing code
- Biomarker
- Cancer of Unknown Primary
- cfDNA
- DNA
- Education
- End of Treatment
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Innovation
- IT
- Lab process
- Learning healthcare system
- Molecular diagnostics
- OncoAct
- Participating hospitals
- Patients' stories
- Personalized treatment
- Quality
- Rare cancers
- Re-use data
- Research
- Scientific publications
- Uncategorized
- Whole genome sequencing
- Working in the cloud
New study using Hartwig Medical Foundation data maps how breast cancer’s genetic makeup shifts when it spreads
Analysis of nearly 1,300 tumor genomes across ten genomic subtypes points to candidate drug targets and biomarkers for metastatic breast …
Hartwig receives CE certification for OncoAct, the first complete IVDR-certified whole-genome cancer diagnostics solution
We are proud to announce that Hartwig Medical Foundation has received CE certification under the European In Vitro Diagnostic Regulation …
Biomarkers Reveal Which Cancer Patients Won’t Benefit From Treatment
Researchers from Vall d’Hebron Institute of Oncology identify genomic signals predicting non-response to cancer therapies in collaboration with Hartwig Medical …
Hartwig and Ultima Expand Collaboration to Advance WGS in Oncology Care
Hartwig and Ultima strengthen collaboration on whole‑genome sequencing Hartwig Medical Foundation to adopt Ultima Genomics’ UG200 sequencing system to accelerate …
From Spreadsheets to Digital Convenience: Hartwig Goes Live With Its Customer Portal
Hartwig Medical Foundation (Hartwig) recently launched its new portal for submitting requests for WGS analysis. For hospitals, this is an important enhancement to …
GMS and Hartwig sign MOU to advance precision medicine for cancer patients
Genomic Medicine Sweden (GMS) and Hartwig Medical Foundation (Hartwig) today signed a Memorandum of Understanding (MoU). This MoU formalises a strategic partnership …
DataNexus connects clinical and genomic data
DataNexus is a project initiated by the Netherlands Cancer Institute–Antoni van Leeuwenhoek (NKI-AvL) to improve data availability by integrating clinical …
GENAYA Extended: More Care and Research
The GENAYA project has been extended by two years. This gives researchers more time to collect genetic tumor data from …
The value of the GENAYA project for patients of the future
The GENAYA project has been extended through 2028. A total of 39 hospitals now participate in the project, which is led by …
From innovation to standard care: real-world impact of whole genome sequencing in oncology
Whole genome sequencing (WGS) is rapidly transforming cancer diagnostics. The Netherlands Cancer Institute (NKI) has already integrated this technology into …
The Role of organoids and Whole Genome Sequencing in precision oncology
Organoids can help determine which patients with metastatic colorectal cancer (mCRC) are likely to respond to chemotherapy and which targeted …
The role of molecular diagnostics in sarcomas
Between Science and Clinical Practice The use of molecular diagnostics in sarcoma care is receiving growing international attention. Recent studies¹ …
Blogs
DataNexus connects clinical and genomic data
DataNexus is a project initiated by the Netherlands Cancer Institute–Antoni van Leeuwenhoek (NKIAvL) to improve data availability by integrating clinical …
Read more
How do you analyze 8,000 Tumor/Normal genomes in under two months?
It has been a long time coming: Hartwig Medical Foundation has transitioned to the GRCh38 (hg38) reference genome! For years, …
Read more
Cancer, a rare disease?
It may come as a surprise to many on this International Rare Disease Day (February 28), that a significant number …
Read moreVideos
From biopsy to patient report
The comprehensive DNA test can provide patients with cancer with more opportunities for treatment. Using the technique of Whole Genome …
Read more
What does Hartwig Medical Foundation do?
Hartwig Medical Foundation is a unique initiative that makes possible progress in the research of treatment of cancer in the …
Read more
Cancers will increasingly meet the definition of ‘rare’ in terms of the molecular profiles that make each tumor unique. The more research we can do into this, the better we will be able to offer patients personalized treatment in the future. Whole Genome Sequencing and studies like DRUP are making an important contribution to this.